Experimental drug offers hope for patients with unstoppable seizures

This study provided expanded access to an experimental drug called SAGE-547 for patients with super-refractory status epilepticus—a severe, life-threatening condition where seizures continue despite multiple standard treatments. The trial aimed to evaluate whether a continuous intravenous infusion of SAGE-547 could help stop these dangerous seizures and was safe for patients, including children as young as six months old. It was designed for patients in intensive care who had already failed to respond to first- and second-line anti-seizure medications.